NCT06124001View on ClinicalTrials.gov

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2026

Conditions
Primary Hepatocellular Carcinoma
Interventions
DRUG

Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))

Intratumoral injection only. Dosing days may be Days 1-2 or Days 1-3.

DRUG

camrelizumab for Injection

Administered once at 3 mg/kg intravenously on Days 8 of each cycle.

All Listed Sponsors
lead

CNBG-Virogin Biotech (Shanghai) Ltd.

INDUSTRY

NCT06124001 - Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter